Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: A case report.
| Title: | Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: A case report. |
|---|---|
| Authors: | Shad AT; Department of Pediatric Hematology/Oncology, The Herman & Walter Samuelson Children's Hospital at Sinai, Baltimore, Maryland.; Department of Pediatric Oncology, Medstar Georgetown University Hospital, Washington, District of Columbia.; Huo JS; Department of Pediatric Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.; Darcy C; Department of Pediatric Oncology, Medstar Georgetown University Hospital, Washington, District of Columbia.; Abu-Ghosh A; Department of Pediatric Oncology, Medstar Georgetown University Hospital, Washington, District of Columbia.; Esposito G; Department of Nuclear Medicine, Medstar Georgetown University Hospital, Washington, District of Columbia.; Holuba MJ; Department of Pediatric Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.; Robey N; Department of Pediatric Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.; Cooke KR; Department of Pediatric Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.; Symons HJ; Department of Pediatric Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.; Chen AR; Department of Pediatric Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.; Llosa NJ; Department of Pediatric Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland. |
| Source: | Pediatric blood & cancer [Pediatr Blood Cancer] 2017 Mar; Vol. 64 (3). Date of Electronic Publication: 2016 Sep 21. |
| Publication Type: | Case Reports; Journal Article |
| Language: | English |
| Journal Info: | Publisher: John Wiley Country of Publication: United States NLM ID: 101186624 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1545-5017 (Electronic) Linking ISSN: 15455009 NLM ISO Abbreviation: Pediatr Blood Cancer Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Hoboken, N.J. : John Wiley, c 2004- |
| MeSH Terms: | Antibodies, Monoclonal/*therapeutic use ; Bone Marrow Transplantation/*adverse effects ; Graft vs Host Disease/*prevention & control ; Hodgkin Disease/*drug therapy ; Immune Tolerance/*immunology ; T-Lymphocytes/*drug effects; Antineoplastic Agents/therapeutic use ; Graft vs Host Disease/immunology ; Hodgkin Disease/therapy ; Adult ; Female ; Humans ; Lymphocyte Depletion ; Nivolumab ; Prognosis ; Transplantation, Homologous ; Young Adult |
| Abstract: | To date, there has been a lack of pediatric experience regarding the efficacy and tolerability of immune checkpoint inhibitors after haploidentical hematopoietic stem cell transplant (HSCT). We present the case of a 22-year-old female with multiple-relapsed Hodgkin lymphoma (HL) who presented with a new relapse after haploidentical (post-haplo) HSCT. Anti-PD-1 therapy with nivolumab resulted in significant objective disease response and clinical improvement without notable side effects, including the absence of a graft-versus-host disease (GVHD). This case report suggests that immune checkpoint inhibition may be safely tolerated even in the setting of haploidentical HSCT, without triggering overt GVHD.; (© 2016 Wiley Periodicals, Inc.) |
| Grant Information: | P30 CA006973 United States CA NCI NIH HHS |
| Contributed Indexing: | Keywords: Hodgkin lymphoma; anti-PD1; haploidentical bone marrow transplant; immunotherapy; nivolumab; relapse |
| Substance Nomenclature: | 0 (Antibodies, Monoclonal); 0 (Antineoplastic Agents); 31YO63LBSN (Nivolumab) |
| Entry Date(s): | Date Created: 20160922 Date Completed: 20170621 Latest Revision: 20220330 |
| Update Code: | 20260130 |
| DOI: | 10.1002/pbc.26257 |
| PMID: | 27650634 |
| Database: | MEDLINE |
Case Reports; Journal Article